Please use this identifier to cite or link to this item:
http://sgc.anlis.gob.ar/handle/123456789/2449
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Elizagaray, Maia Lina | es |
dc.contributor.author | Mazitelli, Ignacio | es |
dc.contributor.author | Pontoriero, Andrea | es |
dc.contributor.author | Baumeister, Elsa | es |
dc.contributor.author | Docena, Guillermo | es |
dc.contributor.author | Raimondi, Clemente | es |
dc.contributor.author | Correger, Enrique | es |
dc.contributor.author | Rumbo, Martín | es |
dc.date.accessioned | 2022-08-17T16:48:28Z | - |
dc.date.available | 2022-08-17T16:48:28Z | - |
dc.date.issued | 2022-08-07 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S2319417022001196?via%3Dihub | - |
dc.identifier.uri | http://sgc.anlis.gob.ar/handle/123456789/2449 | - |
dc.description.abstract | Severe cases of COVID-19 that require admission to the ICU and mechanical ventilation assistance show a high mortality rate with currently few therapeutic options available. Severe COVID-19 is characterized by a systemic inflammatory condition, also called "cytokine storm", which can lead to various multi-organ complications and ultimately death. Lidocaine, a safe local anesthetic that given intravenously is used to treat arrhythmias, has long been reported to have an anti-inflammatory and pro-homeostatic activity. | es |
dc.language.iso | en | es |
dc.relation.ispartof | Biomedical journal | es |
dc.subject | SARS-CoV-2 | es |
dc.subject | COVID-19 | es |
dc.subject | Dexametasona | es |
dc.subject | Inflamación | es |
dc.subject | Interferón | es |
dc.subject | Lidocaína | es |
dc.title | Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.1016/j.bj.2022.07.008 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairetype | Artículo | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS) | - |
crisitem.author.dept | Instituto Nacional de Enfermedades Infecciosas (INEI) | - |
crisitem.author.dept | Departamento de Virología | - |
crisitem.author.dept | Servicio de Virosis Respiratoria | - |
crisitem.author.dept | Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS) | - |
crisitem.author.dept | Instituto Nacional de Enfermedades Infecciosas (INEI) | - |
crisitem.author.dept | Departamento de Virología | - |
crisitem.author.dept | Servicio de Virosis Respiratoria | - |
crisitem.author.parentorg | Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS) | - |
crisitem.author.parentorg | Instituto Nacional de Enfermedades Infecciosas (INEI) | - |
crisitem.author.parentorg | Departamento de Virología | - |
crisitem.author.parentorg | Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS) | - |
crisitem.author.parentorg | Instituto Nacional de Enfermedades Infecciosas (INEI) | - |
crisitem.author.parentorg | Departamento de Virología | - |
Appears in Collections: | Publicaciones INEI |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.